Nipro PharmaPackaging, a provider of glass tubing, glass primary packaging, and medical devices, has launched its Direct-to-Fill (D2F) glass vials.  

These vials incorporate Stevanato Group's advanced EZ-fill technology, providing a ready-to-use solution that meets the stringent demands and growing needs of the pharmaceutical sector. 

The D2F glass vials are washed, depyrogenated, packaged in nest and tub formats, and sterilised.  

In addition, these vials can be directly integrated into aseptic fill-finish processes, enhancing operational efficiency. 

Developed in partnership with leading machine suppliers, the D2F vials are also compatible with a diverse array of fill-finish lines.  

This compatibility ensures quick and easy integration into existing systems, which can significantly accelerate production timelines. 

The design of D2F vials, featuring a nest and tub configuration, minimises glass-to-glass contact, according to Nipro.  

This reduces the risk of breakage, cosmetic defects, and particle generation during transport and handling.  

The result is a product with improved mechanical durability, reduced downtime, and fewer rejections during quality inspections, which can lead to more stable and cost-effective fill-finish operations. 

Nipro PharmaPackaging CEO Stephan Arnold said: “We are excited to introduce D2F glass vials, offering a reliable and efficient RTU packaging solution that addresses the evolving needs of the pharmaceutical industry. 

“These vials exemplify our mission to delivering trust with premium primary pharma packaging solutions.” 

Nipro PharmaPackaging, a part of Nipro Corporation Japan, specialises in developing and manufacturing advanced pharmaceutical packaging products and complete packaging solutions. 

The company serves both early-stage drug development and the enhancement of packaging for existing pharmaceutical drugs.